AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca New Molecular Entities in late-stage pipeline by Year
New Molecular Entities (NMEs) in late-stage pipeline (count)
AstraZeneca New Molecular Entities in late-stage pipeline: 20 in FY2025, up 5.3% from a year earlier.
Latest, FY2025
20
Period ended Dec 31, 2025
Change on a year earlier
+5.3%
19 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“197 projects in development pipeline | 20 NMEs in late-stage pipeline | 125 NME or major LCM projects in Phase II or Phase III | 43 regulatory approvals in major markets (US, EU, CN, JP)”
Source: Clinical Trials Appendix (2025Q4) ↗
Reported in Clinical Trials Appendix (Pipeline at a glance).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Molecular Entities (NMEs) in late-stage pipeline (count) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20 | +5.3% | Clinical Trials Appendix (2025Q4) ↗ |
| FY2024 | Dec 31, 2024 | 19 | +11.8% | Clinical Trials Appendix (2024Q4) ↗ |
| FY2023 | Dec 31, 2023 | 17 | – | Clinical Trials Appendix (2023Q4) ↗ |
Cite this data
StockData. (2026). AstraZeneca New Molecular Entities in late-stage pipeline, annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cta-late-stage-nmes
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.